ReviewDer Internist2008
[Diagnostics and therapy of chronic hepatitis B and C].
Review in Der Internist, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- [Interferon-alfa induced reactivation of sarcoidosis in a patient with chronic hepatitis C].Der Internist · 2010Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapy of chronic hepatitis B (HBV) und C (HCV) virus infection has continuously improved over the last years by the invention of new therapeutic agents for HBV, greater individualization for HCV and more sensitive tests for viral nucleic acids. Prognosis and therapeutic success rates have improved, however, more and more response predicting factors have to be considered prior to and during antiviral treatment to adjust therapy on an individual basis. Thus, in 2007 the German National Treatment Guidelines for HBV infection have been revised. A similar update is planned for chronic HCV infection in the year 2008. This review summarizes recommendations of the German National Hepatitis B Treatment Guidelines and shows current trends in the management of chronic hepatitis C which will be included in the future revised guidelines for hepatitis C. Since treatment of both infections will be characterized by a growing complexity, therapy should only be performed by internists with special experience in hepatology who are able to create individual concepts within evidenced-based treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.